论文部分内容阅读
CVD风险患者,往往也表现异常脂蛋白血症,异常脂蛋白血症指的是:偏低的HDL-C,抬高的甘油三酯,和/或尺寸小的LDL颗粒数量增加。我们建议,患者存在的每个风险因素都进行针对性治疗,并以生活方式干预和药物治疗为重点。在异常脂蛋白血症治疗方面,我们提出以下建议:●大多数CMR成年患者的异常脂蛋白血症治疗,首选他汀类药物;●对于使用他汀类药物治疗的CMR患者,使用apoB测量值来指导治疗的调整;也就是说,在以LDL-C和non-HDL-C为治疗目标之后,如果没有达标,以apoB为治疗目标;●表1总结的治疗目标,可使伴有异常脂蛋白血症的CMR患者在生存方面获益;●需要进行进一步的临床试验,以确定以降低致动脉粥样硬化相关脂蛋白为目的的药物治疗,是否具有安全性和成本效益;●有利于人口减少CVD事件的策略重点,在于生活方式干预。
Patients with CVD risk often also exhibit dyslipoproteinemia, with dyslipoproteinemia referring to low HDL-C, elevated triglycerides, and / or an increase in the number of LDL particles of small size. We recommend that each risk factor for the patient be targeted and focused on life-style interventions and medication. For the treatment of dyslipoproteinemia, we suggest the following: • Treatment of dyslipoproteinemia in most CMR adult patients, with statins preferred; • Use of apoB measurements in CMR patients treated with statins Treatment; that is, apoB is the target of treatment if it is not achieved after LDL-C and non-HDL-C are targeted; • The treatment goals summarized in Table 1 allow patients with abnormal lipoprotein Survival benefit from CMR patients; • Further clinical trials are needed to determine whether it is safe and cost-effective to reduce drug therapy for the cause of atherothrombosis-associated lipoprotein; The strategic focus of the incident is lifestyle intervention.